27.77
0.63 (2.32%)
| Penutupan Terdahulu | 27.14 |
| Buka | 27.33 |
| Jumlah Dagangan | 271,999 |
| Purata Dagangan (3B) | 318,805 |
| Modal Pasaran | 1,288,172,544 |
| Harga / Pendapatan (P/E Ke hadapan) | 250.00 |
| Harga / Jualan (P/S) | 12.79 |
| Harga / Buku (P/B) | 3.07 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -24.54% |
| Margin Operasi (TTM) | -40.48% |
| EPS Cair (TTM) | -0.250 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 29.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.65% |
| Nisbah Semasa (MRQ) | 4.55 |
| Aliran Tunai Operasi (OCF TTM) | 8.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 43.83 M |
| Pulangan Atas Aset (ROA TTM) | -1.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Bercampur | Bercampur |
| Medical Instruments & Supplies (Global) | Bercampur | Bercampur | |
| Stok | BioLife Solutions, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -3.5 |
| Purata | -0.13 |
|
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.47% |
| % Dimiliki oleh Institusi | 101.86% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 31.00 (Northland Capital Markets, 11.63%) | Beli |
| Median | 30.50 (9.83%) | |
| Rendah | 30.00 (HC Wainwright & Co., 8.03%) | Beli |
| Purata | 30.50 (9.83%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 27.25 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Mar 2025 | 30.00 (8.03%) | Beli | 26.80 |
| Northland Capital Markets | 08 Jan 2025 | 31.00 (11.63%) | Beli | 27.69 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Mar 2025 | Pengumuman | BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair |
| 03 Mar 2025 | Pengumuman | BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results |
| 20 Feb 2025 | Pengumuman | BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025 |
| 13 Jan 2025 | Pengumuman | BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |